The Evolving Role of Immunotherapy in Early Stage & Advanced/Metastatic Triple Negative Breast Cancer
April 21, 2021
This presentation will examine the evolving role of immunotherapy in early stage and advanced/metastatic triple negative breast cancer including the evidence for regimens in the management of each as well as current biomarkers.
Learning Objectives
- Examine the evidence for immunotherapy regimens in the management of early stage Triple Negative Breast Cancer
- Examine the evidence for immunotherapy regimens in the management of advanced stage Triple Negative Breast Cancer
- Examine the current biomarkers in breast cancer predicting immunotherapy efficacy
Available Credit
- 1.00 ACPE - Pharmacist
- 1.00 AMA PRA Category 1 Credit(s)™
- 1.00 ANCC
- 1.00 Attendance
- 1.00 JA Credit - AH
- 1.00 Approved for AMA PRA Category 1 Credit(s)™